Sorry, you need to enable JavaScript to visit this website.

Current state-of-the-art in the use of plants for the production of recombinant vaccines against infectious bursal disease virus

TitleCurrent state-of-the-art in the use of plants for the production of recombinant vaccines against infectious bursal disease virus
Publication TypeArticolo su Rivista peer-reviewed
Year of Publication2020
AuthorsRage, E., Marusic Carla, Lico Chiara, Baschieri Selene, and Donini Marcello
JournalApplied Microbiology and Biotechnology
Volume104
Pagination2287-2296
ISSN01757598
KeywordsAgroinfiltration, Animals, Diseases, Escherichia coli, Infectious bursal disease virus, Losses, Manufacture, Molecular farming, Recombinant Proteins, subunit vaccine, transient expression, Vaccines, Veterinary vaccines, Viruses
Abstract

Infectious bursal disease is a widely spread threatening contagious viral infection of chickens that induces major damages to the Bursa of Fabricius and leads to severe immunosuppression in young birds causing significant economic losses for poultry farming. The etiological agent is the infectious bursal disease virus (IBDV), a non-enveloped virus belonging the family of Birnaviridae. At present, the treatment against the spread of this virus is represented by vaccination schedules mainly based on inactivated or live-attenuated viruses. However, these conventional vaccines present several drawbacks such as insufficient protection against very virulent strains and the impossibility to differentiate vaccinated animals from infected ones. To overcome these limitations, in the last years, several studies have explored the potentiality of recombinant subunit vaccines to provide an effective protection against IBDV infection. In this review, we will give an overview of these novel types of vaccines with special emphasis on current state-of-the-art in the use of plants as “biofactories” (plant molecular farming). In fact, plants have been thoroughly and successfully characterized as heterologous expression systems for the production of recombinant proteins for different applications showing several advantages compared with traditional expression systems (Escherichia coli, yeasts and insect cells) such as absence of animal pathogens in the production process, improved product quality and safety, reduction of manufacturing costs, and simplified scale-up. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.

Notes

cited By 0

URLhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85078322489&doi=10.1007%2fs00253-020-10397-2&partnerID=40&md5=3ffc9fa1610b6b80696708a9bdcabf4a
DOI10.1007/s00253-020-10397-2
Citation KeyRage2020